The article examines the influence of different therapeutic options on the clinical status, quality of life and endothelial function in patients with coronary heart disease. The purpose of the study was to assess the effect of therapy on the clinical status and endothelial function of patients with coronary heart disease and additional possibilities for correction of endothelial dysfunction with a fixed combination of meltedonium and gamma-butyrobetaine. We supervised 112 patients with coronary heart disease: 76 of them were with stable coronary heart disease of II-III functional classes and 36 patients were hospitalized with an acute coronary syndrome. We evaluated the effectiveness of additional inclusion to the treatment of patients with coronary heart disease combination of meldonium and gamma-butyrobetaine ("Capicor®"). It is shown that the "Capicor" addition in the complex treatment of patients with coronary heart disease contributes to more pronounced improvement in quality of life according to the Seattle Angina Questionnaire, namely: a significant reduction of angina frequency scale, increased of treatment satisfaction, and improved of disease perception scale. At the same time, the "Capicor" addition to the treatment leads to a more significant positive dynamics of the endothelial functional state compared with patients receiving traditional therapy. The obtained data give grounds to consider that "Capicor" inclusion in the management scheme of patients with stable and unstable course of coronary heart disease is expedient.

Keywords: coronary heart disease, quality of life, endothelial dysfunction, standard therapy, Capicor

Full text: PDF (Ukr) 192K

1. Nebieridze DV. Disfunktsiya endoteliya i ee korrektsiya pri arterialnoy gipertonii. Rus med zhurn. 2006; 14 (2): 27-131. [Russian].
2. Nikitin YuP, Cimonova GI, Khoreva MA i dr. Rol disfunktsii endoteliya v patogeneze ateroskleroza. Ateroskleroz. 2011; 7 (1): 68-77. [Russian].
3. Shabalin AV, Ragino YuI, Lyubimtseva SA, i dr. Vliyanie tsitoprotektsii na okislitelnye protsessy i endotelialnuyu funktsiyu u pozhilykh patsientov s ishemicheskoy boleznyu serdtsa. Ratsionalnaya farmakoterapiya. 2006; 3: 32-6. [Russian].
4. Soboleva GN, Pogorelova OA, Kuznetsova TV, i dr. Vliyanie valsartana, fluvastatina zamedlennogo vysvobozhdeniya i ikh kombinatsii na arterialnoe davlenie, pokazateli lipidnogo obmena i funktsiyu endoteliya u bolnykh gipertonicheskoy boleznyu. Kardiologiya. 2007; 11: 9-13. [Russian].
5. Teregulov YuG, Khusainova DK, Salikhov IG, i dr. K metodologii provedeniya proby i otsenki endoteliy-zavisimoy dilatatsii plechevoy arterii. Ekhografiya. 2004; 5: 217-21. [Russian].
6. Voronkov LG, Shkurat IA, Lutsak EA. Vliyanie mildronata na endoteliy¬-zavisimuyu vazodilatatsiyu u bolnykh s khronicheskoy serdechnoy nedostatochnostyu: dvoynoe slepoe pere¬krestnoe issledovanie. Ratsionalnaya farmakoterapiya v kardiologii. 2008; 2: 38-40. [Russian].
7. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet.1992; 340: 1111-5. https://www.ncbi.nlm.nih.gov/pubmed/1359209
8. Chatzizisis YS, Jonas M, Coskun AU, Beigel R, Stone BV, Maynard C, Gerrity RG, Daley W, Rogers C, Edelman ER, Feldman CL, Stone PH. Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress. Circulation. 2008; 117: 993-1002. https://www.ncbi.nlm.nih.gov/pubmed/18250270. https://doi.org/10.1161/CIRCULATIONAHA.107.695254
9. Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: cardioprotective action through carnitine-¬lowering effect. Trends Cardiovasc Med. 2002; 12 (6): 275-9. https://www.ncbi.nlm.nih.gov/pubmed/12242052
10. Deanfield О, Halcox P, Rabelink T. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115: 1285-95. https://www.ncbi.nlm.nih.gov/pubmed/17353456. https://doi.org/10.1161/CIRCULATIONAHA.106.652859
11. Hosokawa S, Hiasa Y, Tomokane T, Ogura R, Miyajima H, Ohara Y, Ogata T, Yuba K, Suzuki N, Takahashi T, Kishi K, Ohtani R. The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction. Clin Cardiol. 2006; 29 (8): 357-62. https://www.ncbi.nlm.nih.gov/pubmed/16933577
12. Taneva E, Borucki K, Wiens L, Makarova R, Schmidt-Lucke C, Luley C, Westphal S. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol. 2006; 97 (7): 1002-6. https://www.ncbi.nlm.nih.gov/pubmed/16563905. https://doi.org/10.1016/j.amjcard.2005.10.032